ARID1A and neoplasm: We found durable clinical benefit in diverse tumor types, with evidence suggesting multiple potential biomarkers of response to ATRi, including loss of ARID1A, genomic instability, ATM/G1 pathway abnormalities, and high tumor inflammation.